InterAx raises CHF 3 Mio for the commercialization of its systems biology platform

InterAx Biotech AG is a spin off from the ETH Zürich and Paul Scherrer Institute (PSI). The company assists GPCR drug candidate design and selection by...

More details More details

Life Science basic research on the top level

The Paul Scherrer Institute (PSI) is Switzerland’s biggest research institute for natural and engineering sciences. It hosts most of the country’s...

More details

Unprecedented speed and success rate with delivering ligand-bound GPCR structures

Modern drug discovery greatly benefits from knowledge of how a drug interacts with its molecular drug target. Membrane protein drug targets represent a...

More details

leadXpro “unlocks” new targets for structure-based drug discovery

One of the most promising groups of drug targets is that of integral membrane proteins. They are responsible for communicating signals from the outside...

More details

State-of-the-art bioinformatics for better drug discovery

The effect a drug has on the human body depends on how well its active substance find its way to the targeted cells in the body, and on the chemical reactions...

More details

Biosensors Technology Platform for efficient lead discovery

In April 2016, the team at InterAx Biotech AG mounted the nameplate of a newly-born company on the wall of PARK INNOVAARE’s deliveryLAB, thus giving...

More details
Subscribe to Biotech